Sangamo BioSciences Inc. (NASDAQ:SGMO) traded up 5.2% on Monday . The stock traded as high as $4.65 and last traded at $4.64, with a volume of 444,034 shares. The stock had previously closed at $4.41.

SGMO has been the subject of a number of research analyst reports. Wells Fargo & Co. initiated coverage on shares of Sangamo BioSciences in a report on Tuesday, May 3rd. They issued a “buy” rating for the company. Jefferies Group reissued a “buy” rating on shares of Sangamo BioSciences in a report on Friday, August 5th. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Sangamo BioSciences in a report on Friday, May 6th. Zacks Investment Research downgraded shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Finally, Cowen and Company reissued a “buy” rating on shares of Sangamo BioSciences in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $15.58.

The company’s 50 day moving average price is $5.68 and its 200-day moving average price is $6.00. The stock’s market capitalization is $326.26 million.

Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.14. The business earned $3.70 million during the quarter, compared to analysts’ expectations of $5.38 million. During the same period in the prior year, the company earned ($0.17) EPS. Sangamo BioSciences’s quarterly revenue was down 56.0% on a year-over-year basis. On average, equities research analysts predict that Sangamo BioSciences Inc. will post ($1.11) EPS for the current fiscal year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Royce & Associates LLC raised its position in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent reporting period.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.